Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hailun
- Development stage
- Phase 2
- Lead developer
- Inner Mongolia University for Nationalities
- Administration
- Oral
01
Overview
Hailun (also known as Hailun Capsule) is a traditional Mongolian medicine (TMM) developed by the Mongolian Medicine College of Inner Mongolia University for Nationalities. It is formulated as an oral capsule intended for the treatment of patients in the early recovery stage of ischemic stroke, specifically those presenting with blood stasis blocking collaterals syndrome. In traditional Mongolian medicine theory, the preparation is designed to promote blood circulation, resolve blood stasis, and clear the meridians and collaterals to facilitate neurological recovery. It has been evaluated in Phase II clinical trials in China to assess its safety and efficacy in improving functional outcomes following a stroke.
- Brand names
- Hailun Capsule
- Other names
- Hailun Jiaonang海伦胶囊
Beyond the preview
Go deeper on Hailun.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hailun.